With larger generic companies facing growth challenges in the US in FY27E, Ajanta Pharma, analysts believe, offers a strong ...
Q3 2025 Management View CEO Reshma Kewalramani highlighted "Vertex delivered strong performance across the board in Q3 with ...
UBS sees significant potential for further earnings upgrades, even after factoring in some moderation in trading volumes from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback